98
Participants
Start Date
August 28, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Dacarbazine
Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)
onfekafusp alfa
L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day
AOU San Luigi Gonzaga, Orbassano
Institut Paoli-Calmettes, Marseille
Hopital Jean Minjoz, Besançon
Institut Claudius Regaud, Toulouse
Institut régional du Cancer de Montepellier - ICM Val d'Aurelle, Montpellier
Münster University Hospital, Münster
Centre Jean Perrin, Clermont-Ferrand
Institut Bergonié, Bordeaux
Centre Léon Bérard, Lyon
Institut Gustave Roussy, Villejuif
Helios Klinikum Bad Saarow, Bad Saarow
Helios Klinikum Berlin- Buch, Berlin
Klinik rechts der Isar, TU München, München
IRCCS - Istituto Ortopedico Rizzoli, Bologna
IRCCS Fondazione del Piemonte per l'Oncologia Istituto per la Ricerca e la Cura del Cancro di Candiolo, Candiolo
Szpital Pomorski Im. PCK, Gdynia
Maria Sklodowska Curie National Research Institute of Oncology, Warsaw
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario Virgen de La Victoria, Málaga
Hospital Universitario de Canarias, San Cristóbal de La Laguna
Hospital Universitario Donostia, San Sebastián
Hospital Clínico Universitario de Valencia, Valencia
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Philogen S.p.A.
INDUSTRY